MARKET

RNAC

RNAC

Cartesian
NASDAQ
0.9900
-0.3600
-26.67%
After Hours: 1.030 +0.04 +4.04% 19:05 12/01 EST
OPEN
1.170
PREV CLOSE
1.350
HIGH
1.200
LOW
0.9840
VOLUME
3.72M
TURNOVER
0
52 WEEK HIGH
1.990
52 WEEK LOW
0.7850
MARKET CAP
160.31M
P/E (TTM)
-4.2092
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's Intraday Session
Neximmune stock moved upwards by 540.4% to $11.07 during friday's regular session. Neximmune's market cap is $218.1 million. Generation bio shares rose 31.81% and altimmune shares rose 28.48% during the session.
Benzinga · 3d ago
Redhill Biopharma, Ampio Pharmaceuticals among healthcare movers
Neximmune, altimmune and altimmune among healthcare movers. Redhill biopharma, ampio pharmaceuticals among healthcare losers. S&p 500 health care sector down 0.05%. Health care equipment & services contributes 0.13% to the index.
Seeking Alpha · 3d ago
Cartesian: [Amend]Registration statement under Securities Act of 1933
Press release · 3d ago
Cartesian: Current report
Press release · 11/27 22:11
Weekly Report: what happened at RNAC last week (1120-1124)?
Weekly Report · 11/27 10:53
Cartesian: General statement of acquisition of beneficial ownership
Press release · 11/22 23:16
Weekly Report: what happened at RNAC last week (1113-1117)?
Weekly Report · 11/20 10:51
Cartesian: Initial statement of beneficial ownership of securities
Press release · 11/17 15:16
More
About RNAC
Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.

Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.